Candesartan Cilexetil-hydrochlorothiazide

Candesartan Cilexetil-hydrochlorothiazide

Candesartan Cilexetil-hydrochlorothiazide Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT. THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS.

Lidocaine should be used with extreme caution if the mucosa in the area of application has been traumatized, since under such conditions there is the potential for rapid systemic absorption.

Life-threatening and fatal events in infants and young children

Postmarketing cases of seizures, cardiopulmonary arrest, and death in patients under the age of 3 years have been reported with use of Lidocaine Viscous 2% when it was not administered in strict adherence to the dosing and administration recommendations. In the setting of teething pain, Lidocaine Viscous 2% should generally not be used. For other conditions, the use of the product in patients less than 3 years of age should be limited to those situations where safer alternatives are not available or have been tried but failed.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Lidocaine Viscous 2% (Lidocaine Hydrochloride Oral Topical Solution USP) is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.

History

There is currently no drug history available for this drug.

Other Information

Lidocaine Viscous 2% (Lidocaine Hydrochloride Oral Topical Solution USP) contains a local anesthetic agent and is administered topically. Lidocaine Viscous 2% (Lidocaine Hydrochloride Oral Topical Solution USP) contains lidocaine hydrochloride, which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-,monohydrochloride, and has the following structural formula:

Lidocaine Viscous Structural Formula

Themolecular formula oflidocaineis C14H22N2O. Themolecularweight is 234.34.

Composition of Solution:

Each mL contains 20 mg (2%) of lidocaine hydrochloride and the following inactive ingredients: carboxymethylcellulose sodium, flavoring, methylparaben, propylparaben, saccharin sodium and water.

Candesartan Cilexetil-hydrochlorothiazide Manufacturers


  • Par Pharmaceutical Inc.
    Candesartan Cilexetil-hydrochlorothiazide (Candesartan Cilexetil And Hydrochlorothiazide) Tablet Candesartan Cilexetil-hydrochlorothiazide (Candesartan Cilexetil Hydrochlorothiazide) Tablet [Par Pharmaceutical Inc.]

Login To Your Free Account